Episode
Isomorphic Labs $2.1 Billion Series B: Sovereign Wealth Bets on DeepMind's Drug Design Engine and the Race to AI Designed Therapeutics - May 17, 2026
- Published
- May 17, 2026
- Duration seconds
- 908
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/dx-today-no-hype-podcast-news-about-ai-dx-6434212/episodes/isomorphic-labs-2-1-billion-series-b-sovereign-wealth-bets-on-deepmind-s-drug-design-engine-and-the-race-to-ai-designed-therapeutics-may-17-2026/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/dx-today-no-hype-podcast-news-about-ai-dx-6434212/isomorphic-labs-2-1-billion-series-b-sovereign-wealth-bets-on-deepmind-s-drug-design-engine-and-the-race-to-ai-designed-therapeutics-may-17-2026.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Send us Fan Mail Isomorphic Labs $2.1 Billion Series B: Sovereign Wealth Bets on DeepMind's Drug Design Engine and the Race to AI Designed Therapeutics - May 17, 2026 Demis Hassabis's DeepMind spinout just closed a $2.1 billion Series B led by Thrive Capital with new participation from Temasek, CapitalG, the UK Sovereign AI Fund, and Abu Dhabi's MGX. Rick and Laura unpack what the IsoDDE engine, the Novartis, Eli Lilly, and Johnson & Johnson partnerships, and a Phase one trial target by ...